Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation

... Researchers concluded Oncotype Dx and the FOXA1 marker can potentially be used interchangeably if ... have over competitive tests will help put this marker on a rapid commercial track and support our ... in women with early stage disease. Clearly, this marker is a tremendous addition to Clarient's rich menu ...

New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando

... studies." Researchers hope that VENDYS, by measuring a dynamic marker of vascular disease, can fill the gap in existing cardiovascular risk ... Furthermore, unlike coronary calcium or carotid IMT, it is a dynamic marker and changes quickly with the progression and regression of the ...

Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test

... cardiovascular diseases. The new, clinically validated heart disease risk marker is included with the VAP Cholesterol Test at no added cost. "The new ... the apoB/apoAI ratio is superior to all other cardiovascular disease risk marker ratios." ApoAI is the main protein component of protective HDL ...

International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"

... Immunoglobulin free light chains (FLC) in serum are an important tumour marker present in patients suffering from MM and associated malignancies. The ... regimes being assessed. Freelite has been used as a sensitive marker for the efficacy of some of these newer treatments and has helped ...

RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease

... First in class drug illustrates early signal of transport of key amyloid marker from brain TSX Exchange Symbol: RVX CALGARY, Nov. 10 ... that treatment with RVX-208 resulted in a positive trend on an important marker of cognitive function and Alzheimer's disease, Amyloid-beta40 is an ...

LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker

... -- LI-COR Biosciences introduces a new, novel protein molecular weight marker for detection on the Odyssey(R) Infrared Imaging system. The Odyssey ... and fluoresces in the 700 and 800 nm channels of the Odyssey System. The marker was designed for use with polyacrylamide gels and can be used to visualize ...

PETCO Adds Canine Heritage Breed Test to its Innovative Assortment

... . Developed by MetaMorphix, Inc. (MMI), a world leader in DNA based marker systems, the non-invasive CHBT test includes a cheek swab that is rubbed ... As a world-leader in the discovery and commercialization of DNA-based marker systems that enhance the ability to identify individual dogs, verify ...

ARIUS presents new findings for anti-cancer antibody programs at AACR

... being manufactured for human clinical studies. It targets CD44 which is a marker of cancer stem cells in a broad range of solid cancers and AML. The first ... capacity of AML cancer stem cells. CD9 is the first description of a marker that is differentially expressed on cancer versus normal stem cells. ...

CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)

... The HemeScan(TM) Test Provides Prognostic marker Precision and Simultaneous Diagnostic Monitoring ... in the treatment and care of CLL patients. The test provides prognostic marker precision with simultaneous diagnostic monitoring of the entire genome in ...

Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP

... for NT-proBNP on the European market. NT-proBNP is a key cardiac marker for a broad array of cardiovascular conditions, including the diagnosis ... test kits for the cardiac markers NT-proBNP and cTnI. The marker specific test cartridge contains the 4castchip(R) in a user friendly ...

CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy

... present in different amounts, and reports the relative amounts of each marker and the percentage of each co-localized marker within the sample. At the heart of the Nuance 2 is the Flex(TM) liquid ...

SEQUENOM Announces Launch of MassARRAY Compact 96 System

... acid analysis applications including SNP genotyping and allelotyping, CNV analysis, quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. About SEQUENOM SEQUENOM ...

Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing

... a selectable "marker." As the stem cells begin to differentiate into different terminal cell types (e.g. heart, blood, neural cells, etc.), the marker allows researchers to identify and select a particular cell type (e.g. heart cells) and produce a highly purified and functional cell population. ...

New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance

... test services range from HIV diagnostic testing to monitoring HIV viral load, determining a viral genotype, and testing for the HLA-B*5701 genetic marker as an aid in predicting a hypersensitivity reaction to abacavir (Ziagen(R)), an antiretroviral therapy. About HIV and AIDS HIV, or the ...

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

... with docetaxel was also well tolerated and escalation to 1000 mg OGX-427 with docetaxel will be evaluated next. Circulating Tumor Cell and Tumor marker Results Circulating tumor cells (CTCs), an emerging metric to assess treatment effect, was evaluated at baseline before treatment and during ...

Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners

... Company's ability to fund development of new diagnostic tests and novel markers and the amount of resources the Company determines to apply to novel marker development and commercialization, failure to obtain FDA clearance or approval for particular applications, the Company's ability to compete with ...

Recombinant C-Reactive Protein

... Protein product line to include recombinant C-Reactive Protein. C-Reactive Protein is a protein found in the blood that operates as a marker for inflammation, meaning its presence indicates an increased state of inflammation in the body. Inflammation is a normal response to a number of ...

DecisionQ Partners With Thomas Jefferson University to Reveal Insights for Cancer Therapy

... of decision analysis, statistics and machine learning have developed the technology and approach that DecisionQ applies in creating MMIA's (multi marker interpretive assays), greatly enhancing the quality of human judgment in an interactive, real-time environment at a low marginal cost. "More ...

Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

... rifampicin, a commonly used first-line drug for treatment of the disease. Many studies have shown that rifampicin resistance is a reliable surrogate marker of strains that are multidrug-resistant TB (MDR-TB), and the frequency of MDR-TB is increasing in the EU. The test is expected to enable clinicians ...

Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting

... Research Institute on work done in collaboration with scientists from Isis and titled "Molecular Control of RNA Alternative Splicing by sigma RNA, a marker for Carcinomas" showed that antisense inhibition of Malat-1 altered the splicing of multiple mRNAs. Altering splicing results in the production of ...

Novel CU-Boulder technique shrinks size of nanotechnology circuitry

... edges" of the lines using a halo of ultraviolet light, trimming the width of the lines significantly. "We are essentially drawing a line with a marker on a nanotechnology scale and then erasing its edges," said McLeod. The method offers potential new approaches in the search for ways to shrink ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... of a new BiTE antibody program because CEA is widely expressed on the surface of human carcinoma cells. In its soluble form, CEA serves as a marker in patients' blood for progression of colorectal and other forms of solid cancers. Conventional CEA-targeting antibodies can be blocked by soluble ...

Immunotherapy-Based Provisional Patents Mark Significant Discovery

... uses. From a diagnostic standpoint, tests can be created to diagnose the presence or location of cancer in serum or in tissue by the addition of marker substances to the antibodies. From a therapeutic standpoint, these antibodies, once prepared for human use, may possibly be used as a therapy against ...

Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)

... of TB, but also identifies whether it is resistant to Rifampicin, a common first-line drug for treatment of the disease and a reliable surrogate marker of strains that are multidrug-resistant (MDR-TB). The test is expected to enable physicians to dramatically improve patient outcomes -- possible only ...

Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando

... studies, including INTERHEART and the AMORIS trials, have clearly shown the apoB/apoAI ratio to be superior to all other cardiovascular disease risk marker ratios. "ACC 2009 represents an excellent setting in which to convey the unique benefits of advanced cholesterol profiling to medical ...

Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008

... Company's ability to fund development of new diagnostic tests and novel markers and the amount of resources the Company determines to apply to novel marker development and commercialization, failure to obtain FDA clearance or approval for particular applications, the Company's ability to compete with ...

New research identifies faster detection of viruses

... and also will enable portable diagnostic devices in a hospital environment for a range of testing not just viruses, but also genomic markers and marker proteins." ...

Singulex Closes $19 Million Financing Round

... the company will focus on cardiovascular disease risk diagnostics using its assay platform for the biomarker c Troponin I (cTnI), a well-validated marker for cardiac necrosis. "Singulex's steady progress in publishing strong data from premier medical schools in the country indicated that the ...

Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial

... sPLA2, a clinically meaningful and statistically significant reduction in "bad" LDL cholesterol, and a reduction in C-reactive protein, a known marker of inflammation. About Acute Coronary Syndrome Acute coronary syndrome is a heart condition characterized by chest pain occurring at ...

Highlights of Economic and Business Growth in the Tampa Bay Region (News Briefs)

... life sciences industry. Biopsy Sciences develops new and innovative products for the medial market including the HydroMARK, a breast biopsy site marker that helps patients by replacing lengthy mammogram-guided wire localization procedures with quick, accurate ultrasound-guided localization procedures ...

SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor

... types have been reported to overexpress the Pim kinase family of proteins at a high frequency. Overexpression of Pim-1 kinase has been shown to be a marker of poor prognosis in these tumors. A second Phase I/II study is being planned in patients with refractory leukemias in which Pim kinases are also ...

Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated

... of ARX201 as an option for the treatment of adult growth hormone deficiency (AGHD). In the 26-week study, normal levels of IGF-I, a marker for hGH activity, were maintained with injections given once a week. The clinical trial results were presented today at the International Congress ...

The Binding Site Announces Trading Update for Year Ended September 30th 2008

... treatment of multiple myeloma with new drugs becoming available and new treatment regimes being assessed. Freelite has been used as a sensitive marker for the efficacy of some of these newer treatments and has helped clinicians gain a clear understanding of how some of these drugs are benefiting ...

RVX-208 Data Demonstrates Increase in Functional HDL Particles

... the actively treated group compared to control. Furthermore, sera from subjects were assessed for ABCA1 mediated cholesterol efflux as a predictive marker for reverse cholesterol transport. Again, ABCA1-dependent cholesterol efflux change increased by 10% (P=0.03) and was found to correlate with ...

Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients

... a statistically significant effect on several key symptom categories of allergic rhinitis: it correlates nicely with the nasal lavage inflammatory marker data," said Morria president, Yuval Cohen. "This is a potent indication that MRX-4 functions as an intra-nasal anti-inflammatory drug for allergic ...

James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30

... related tests for breast and other cancers using its proprietary Ziplex System. Dr. Wittliff's discoveries and development of a unique tumor marker database resulted in the filing of new patents for the University of Louisville and the licensing of his technologies. About Xceed Molecular ...

Monogram Announces 2008 Third Quarter Financial Results

... and planned clinical studies," added Young. "Also in 2009, our goal is to further expand HERmark with the planned introduction of an additional marker to HERmark that may inform decisions about potential combination therapy, not just Herceptin therapy." VeraTag(TM) Oncology Platform "With our ...

CISBIO Bioassays Launches Chromoa(TM) Chromogranin A ELISA Kit

... Company's Expertise in Chromogranin A Tumor Detection marker Technology Now Applied to Universal Technique BAGNOLS-SUR-CEZE, France, September 23 /PRNewswire/ -- CISBIO Bioassays, a member ...

Synvista Therapeutics Posts Letter to Stockholders on Web Site

... may predict outcomes in patients with heart failure. Our product candidate alagebrium has been shown to affect CML levels in animal models and the marker is being tracked in our alagebrium Phase 2 programs involving a target of 260 patients. As a result of accumulating data on the connection between ...

33rd ESMO Congress in Stockholm, 12-16 September 2008

... phase II trial of patients with inoperable pancreatic cancer, Prof. Matthias Lohr from the Karolinska Institute reports. Late breaking data: Gene marker indicates doubling of survival time in advanced colorectal cancer treated with cetuximab (Embargoed until Tuesday, 16 September 2008, 08:30 CEST) ...